Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-GPC3 in Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
NCT07487402Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-GPC3 in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoint: Adverse Events. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Meta10-GPC3
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07487402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487402.